Neurodegenerative disorders are rising worldwide, yet most approved drugs merely temper symptoms. Nucleic Acids and Precision Therapies for Neuroprotection addresses this therapeutic shortfall directly, tracing how antisense oligonucleotides, RNA interference agents, mRNA platforms, aptamers, and CRISPR-class editors are redefining what "treatable" means for Alzheimer's, Parkinson's, ALS, Huntington's disease, and Multiple Sclerosis.
Rather than cataloguing modalities in isolation, the book lays out an end-to-end translational roadmap from target identification and sequence optimisation to blood-brain barrier traversal, immunogenicity management, scalable manufacturing, and ethical oversight. Delivery science (including viral, nanoparticle, and hybrid vectors), AI-enabled biomarker discovery, adaptive trial architectures, and shifting global regulatory frameworks are viewed as interlocking elements of a single development pathway.
By aligning disparate scientific "dialects" into a shared, practice-oriented language, Nucleic Acids and Precision Therapies for Neuroprotection offers what the field currently lacks: a cohesive guide for moving nucleic acid therapeutics from concept to clinic with precision. Researchers, clinicians, regulators, and industry teams will find pragmatic frameworks, comparative tables, and decision points that shorten the path between mechanistic insight and patient impact without sacrificing rigour or transparency.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Academic, Postgraduate, Professional Practice & Development, and Professional Reference
Illustrationen
4 farbige Abbildungen, 35 s/w Photographien bzw. Rasterbilder, 4 Farbfotos bzw. farbige Rasterbilder, 3 s/w Zeichnungen, 43 s/w Tabellen, 38 s/w Abbildungen
43 Tables, black and white; 3 Line drawings, black and white; 4 Halftones, color; 35 Halftones, black and white; 4 Illustrations, color; 38 Illustrations, black and white
Maße
Höhe: 297 mm
Breite: 210 mm
Gewicht
ISBN-13
978-1-032-68673-8 (9781032686738)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Dr. K. Trideva Sastri Koduru is a faculty member in Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA-based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR's Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri's research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences
1. Introduction to Neurodegenerative Disorders
2. Traditional Therapies for Neurodegenerative Diseases
3. Nucleic Acid Therapies for Neurodegenerative Disorders
4. Antisense and RNA-Interference Strategies for Neurodegeneration
5. Aptamer and mRNA Platforms for Receptor Targeting and Protein Replacement
6. Genome Editing and Next-Generation Nucleic-Acid Tools
7. Precision Medicine and Nucleic Acid Therapies for Neurodegenerative Disorders
8. Challenges in the Development and Application of Nucleic Acid Therapies for Neurodegenerative Disorders
9. Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative Disorders
10. AI and Nucleic Acid Therapeutics in Neurodegenerative Disease
11. Clinical trials of Nucleic Acid therapies for neurodegenerative disorders
12. Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative Disorders
13. Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative Disorders
